Article Text

Download PDFPDF
Rare case of type B insulin resistance in association with systemic lupus erythematosus: illustrating diagnostic and management challenges
  1. Aaisha Saqib1,
  2. Yik Man2,
  3. Rayan Ismail1 and
  4. Dulmini Kariyawasam1
  1. 1Diabetes & Endocrinology, Guy's and St Thomas' Hospitals NHS Trust, London, UK
  2. 2Rheumatology, Guy's and St Thomas' Hospitals NHS Trust, London, UK
  1. Correspondence to Dr Aaisha Saqib; aaishasaqib{at}nhs.net

Abstract

A 42 year-old Caribbean woman with, known type 2 diabetes, was admitted with worsening fatigue, arthritis and rashes. She was diagnosed with multisystem systemic lupus erythematosus and was initially treated with systemic steroids. During this admission, she had persistently elevated capillary glucose levels with insulin requirements over 8 U/kg/day that still did not control her blood glucose levels. Due to her profound hyperglycaemia, serum samples of fasting insulin, C-peptide, paired with blood glucose were analysed, which confirmed significant hyperinsulinaemia. Further analysis confirmed the presence of insulin receptor antibodies consistent with type B insulin resistance.

She was started on intravenous cyclophosphamide (Euro-Lupus regimen) along with continuous glucose monitoring system. After completing her six cycles of cyclophosphamide, she no longer required insulin treatment. The goal of therapy for our patient with confirmed type B insulin resistance was to manage hyperglycaemia with high doses of insulin until autoantibodies were eliminated with immunosuppressive therapy.

  • systemic lupus erythematosus
  • diabetes
  • metabolic disorders

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Twitter @Aaisha_Saqib

  • Contributors AS and YM: contributed to the management of the case and coauthored the case report. RI: contributed to the management of the case, revised initial draft and got patient consent. DK: lead the management of the case and revised the final version.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.